Reduction of Alcohol Drinking in Young Adults by Naltrexone: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Naltrexone, an opioid antagonist, may facilitate reduction in drinking among young adults. We compared the efficacy and safety of naltrexone administered daily plus targeted dosing with placebo to reduce drinking in young adults who engage in heavy drinking. METHOD: A randomized, double-blind, placebo-controlled study was conducted in an outpatient research center in March 2008-January 2012. Participants were aged 18-25 years and reported ≥ 4 heavy drinking days in the prior 4 weeks. Interventions included naltrexone 25 mg daily plus 25 mg targeted (at most daily) in anticipation of drinking (n = 61) or daily/targeted placebo (n = 67). All participants received a personalized feedback session and brief counseling every other week. Primary outcomes were percent heavy drinking days and percent days abstinent over the 8-week treatment period. Secondary outcomes included number of drinks per drinking day and percentage of days with estimated blood alcohol concentration (BAC) levels ≥ 0.08 g/dL. RESULTS: Of 140 randomized patients, 128 began treatment, comprising the evaluable sample. During treatment, percent heavy drinking days (naltrexone: mean = 21.60, SD = 16.05; placebo: mean = 22.90, SD = 13.20) (P = .58) and percent days abstinent (naltrexone: mean = 56.60, SD = 22.52; placebo: mean = 62.50, SD = 15.75) (P = .39) did not differ by group. Naltrexone significantly reduced the number of drinks per drinking day (naltrexone: mean = 4.90, SD = 2.28; placebo: mean = 5.90, SD = 2.51) (P = .009) and percentage of drinking days with estimated BAC ≥ 0.08 g/dL (naltrexone: mean = 35.4, SD = 28.40; placebo: mean = 45.7, SD = 26.80) (P = .042). There were no serious adverse events. Sleepiness was more common with naltrexone. CONCLUSIONS: Naltrexone did not reduce frequency of drinking or heavy drinking days, but reduced secondary measures of drinking intensity. While effects were modest, the risk-benefit ratio favors offering naltrexone to help young adult heavy drinkers reduce the amount of alcohol they drink. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00568958.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988
Hingson, R. W., Zha, W., & Weitzman, E. R. (2009) · Journal of Studies on Alcohol and Drugs, Supplement · doi:10.15288/jsads.2009.s16.12 · Cited by 1,184 · cited 4×
“J Clin Psychiatry 2015;76(2):e207–e213”
InfluentialIndividual-level interventions to reduce college student drinking: A meta-analytic review
Carey, K. B., Scott-Sheldon, L. A. J., Carey, M. P., & DeMartini, K. S. (2007) · Addictive Behaviors · doi:10.1016/j.addbeh.2007.05.004 · Cited by 699 · cited 1×
“Exclusion criteria were (1) presence of current, clinically significant physical disease/abnormality according to history, physical examination, or laboratory evaluation; (2) presence of serious psychiatric illness by history or examination; (3) diagnosis of DSM-IV drug dependence other than nicotine in the past 12 mo…”
Self-citationAnton, R. F., Drobes, D. J., Voronin, K., Durazo-Avizu, R., & Moak, D. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1720-7 · Cited by 135 · cited 1×
“07) Highest level of education, n (%) High school or less 18 (14) 7 (12) 11 (16) Some college 72 (56) 33 (54) 39 (58) College/postbaccalaureate degree 38 (30) 21 (34) 17 (25) Enrolled student status, n (%) 91 (71) 43 (71) 48 (72) Smoke at least weekly, n (%) 38 (30) 18 (30) 20 (30) Alcohol use diagnosis, (%) No diagno…”
Cited by
Volkow, N. D., & Blanco, C. (2023) · World psychiatry · doi:10.1002/wps.21073 · Cited by 503
Palpacuer, C., Duprez, R., Huneau, A., Locher, C., Boussageon, R., Laviolle, B., & Naudet, F. (2018) · Addiction · doi:10.1111/add.13974 · Cited by 172
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“Additional recent trials demonstrate that naltrexone reduces the rewarding effects of alcohol [54, 55], alcohol craving [40, 56], drinks per drinking day [57], and relapse rates [58, 59], strengthening the initial findings.”
Adolescent Substance Use Disorder Treatment: an Update on Evidence-Based Strategies
Fadus, M. C., Squeglia, L. M., Valadez, E. A., Tomko, R. L., Bryant, B. E., & Gray, K. M. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1086-0 · Cited by 127
Pharmacological Treatment of Youth Substance Use Disorders
Squeglia, L. M., Fadus, M. C., McClure, E. A., Tomko, R. L., & Gray, K. M. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0009 · Cited by 79
Metadata
- Authors
- O’Malley, S. S., Corbin, W. R., Leeman, R. F., DeMartini, K. S., Fucito, L. M., Ikomi, J., Romano, D. M., Wu, R., Toll, B. A., Sher, K. J., Gueorguieva, R., & Kranzler, H. R.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2015-02-25
- Volume
- 76
- Issue
- 02
- Pages
- e207-e213
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2002623313
- Cited by
- 79
- References
- 5
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.